A Philadelphia cell and gene therapy contract manufacturer is emerging from stealth mode with $64 million in funding, a custom-built facility at the Navy Yard and a veteran health care executive as its new CEO.
VintaBio was founded in 2020 by Junwei Sun and Dr. Shangzhen Zhou, who developed the first viral vectors used for life-saving therapies, including the cell therapy that cured Children's Hospital of Philadelphia patient Emily Whitehead of a pediatric cancer.
VintaBio is being led by newly…
